| Document |
Document Title |
|
WO/2010/090304A1 |
Disclosed is an excellent agent for treatment or prevention of dementia, schizophrenia and the like, which has a serotonin 5-HT5A receptor modulating activity. An acylguanidine derivative represented by formula (I), wherein guanidine is ...
|
|
WO/2010/074591A1 |
The invention relates to pharmaceutical chemistry, in particular to new biologically active substances (BAS) and to the properties thereof, namely, to creatine derivatives of general formula : NH=C(NH2)-N(CH3)- CH2-CO-NH-R٠X, wherein R ...
|
|
WO/2010/074268A1 |
Provided are a novel arginine derivative and a cosmetic which is highly compatible with the skin and hair, has excellent effects of softening and conditioning the skin, shows little stickiness or skin-tautness, and has a good texture in ...
|
|
WO/2010/060231A1 |
The present invention provides a kind of nitroguanidine compounds, its preparation method and uses. The structure of the compound is as follows of formular I, in which R1 is saturated or unsaturated C1-10 aliphatic alkyl, benzyl or subst...
|
|
WO/2010/032771A1 |
Disclosed is a novel amino acid derivative having excellent analgesic activity. The amino acid derivative is a novel compound which exhibits excellent analgesic activity not only with respect to nociceptive pain model animals, but also w...
|
|
WO/2010/024225A1 |
A compound represented by general formula (1), a tautomer thereof, or a salt of the compound or tautomer, which is useful as a bactericide/disinfectant. (In the formula, R1 represents a hydrogen atom, an optionally substituted alkyl grou...
|
|
WO/2010/017089A1 |
Method of detecting Symmetrical dimethyl arginine (SDMA) in biological samples. SDMA analogs for generating anti-SDMA antibodies having little or no cross- reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine....
|
|
WO/2010/014022A1 |
A process for the preparation of Imatinib according to the invention consists in converting the 2-methyl-5-halogenoaniline of the Formula 2 into the salt of the 2-methyl-5- halogenophenylguanidine of the Formula 3, which is then condense...
|
|
WO/2010/010048A1 |
The present invention relates to a blend containing one or more epoxy resins and a mixture, which contains 0.3 to 0.9 amine equivalent per epoxy equivalent of the epoxy resin used of a hardening component a) and a compound of the formula...
|
|
WO/2010/010045A1 |
The present invention relates to a mixture containing at least three hardener components a1), a2), and b), wherein the ratio of the hardener component a1) to a2) is in the range of 0.1-10 to 1, and the hardener component b) is present wi...
|
|
WO/2010/010047A1 |
The present invention relates to a method for producing molded bodies, wherein a blend is used to harden the mold, said blend containing one or more epoxy resins and a mixture, and the hardening component a) in the range of 0.3 to 0.9 am...
|
|
WO/2010/004231A2 |
The invention relates to novel compounds having the following formula (I) in which: n is an integer from 1 to 12, in particular from 1 to 8, m and m' are, independently of one another, integers from 0 to 8, - q and q' are, independently ...
|
|
WO/2009/156241A1 |
The invention relates to ether guanidines of general formulae (I) and/or the salts or hydrates thereof, wherein R1 = -CH2-CH2-CH2-O-R3 where R3 is independently hydrocarbon groups with a minimum of 10 carbon atoms, some of the ether guan...
|
|
WO/2009/148869A1 |
Ligand functionalized substrates, methods of making ligand functionalized substrates, and methods of using functionalized substrates are disclosed.
|
|
WO/2009/144527A1 |
In this invention, a new 1,1 -dimethylbiguanide Glycinate salt was synthesised, called metformin Glycinate. This salt exhibits advantages over other metformin salts. These advantages are due, in the first place, to the fact that the glyc...
|
|
WO/2009/142715A1 |
The invention provides a novel apparatus and method for preparing a solution of a shear sensitive material.
|
|
WO/2009/142892A1 |
Provided herein are novel cationic lipids, compositions comprising the cationic lipids, and methods of using the cationic lipids. In some claims, the cationic lipids have cytotoxic activity and can be used alone or in combination with a ...
|
|
WO/2009/133264A2 |
The present invention relates to a method for preparing macromolecular species with a modified surface, comprising a step (e) in which macromolecular species (M), initially carrying -OH and/or ‑SH functions, are brought into contact wi...
|
|
WO/2009/132786A1 |
A granulated dicyandiamide material having a high abrasion resistance and good solids flow and having a) an average primary crystallite size of from 0.01 to 1 mm and b) an average agglomerate size of from 0.2 to 20 mm is described. The g...
|
|
WO/2009/123487A1 |
The present invention relates to a compound of formula I (I) wherein X is hydrogen, R1, RIC(O), R1C02, or a C0X2 inhibitor, wherein R1 is C1-20 alkyl, aryl, arylalkyl, alkyloxy or arylalkyloxy; wherein Y is 0R2, NHR3 N(R3)2, or a COX inh...
|
|
WO/2009/118307A2 |
The invention relates to novel compounds having a guanidine structure and to the use of same as organopolysiloxane polycondensation catalysts.
|
|
WO/2009/113092A2 |
Disclosed herein is the process for the preparation of 1-(4-chlorophenyl)-5- isopropyl-biguanide hydrochloride (Proguanil hydrochloride), Formula (I), an antimalarial agent.
|
|
WO/2009/106713A2 |
The subject of the present invention is the development of a new family of cationic lipids and the use thereof as vectors for in vitro, ex vivo and in vivo delivery of biologically active agents.
|
|
WO/2009/100890A1 |
The invention discloses a product made of O-acylated hydroxycarboxylic acid and amino acid of the general formula (I), where AS is a proteinogenic or synthetically produced amino acid of the general formula (II), which is preferably D, L...
|
|
WO/2009/100267A1 |
The present invention provides methods to produce arginine bicarbonate more rapidly and efficiently than conventional methods.
|
|
WO/2009/087395A1 |
The present invention relates to compounds which find use as weight reducing agents, and find use in treating obesity and/or excess adiposity.
|
|
WO/2009/082020A1 |
Disclosed is a compound having high reactivity with a functional group such as an aldehyde group. Specifically disclosed is a compound represented by the general formula (1) or a salt thereof. R1-NH-O-L1-D-L2-A (1) wherein R1 represents ...
|
|
WO/2009/080818A2 |
The adrenergic receptors or adrenoceptors are a family of G-protein coupled receptors split into α and β subclasses. The adrenoceptors have important roles in regulating a myriad of physiological conditions and their malfunction has be...
|
|
WO/2009/076741A1 |
The present invention describes compounds produced from a Creatinol molecule and a fatty acid molecule. The compounds being in the form of Creatinol-fatty compounds bound by an ester linkage, or mixtures thereof produced by reacting Crea...
|
|
WO/2009/038396A2 |
Disclosed herein are a novel dicarboxylic acid salt of N,N- dimethylimidodicarbonimidic diamide, a preparation method thereof and a pharmaceutical composition comprising the same. More specifically, disclosed herein are a novel dicarboxy...
|
|
WO/2009/036175A2 |
The present invention relates to a family of guanidine-based F1F0-ATPase inhibitors, e.g., mitochondrial F1F0-ATPase inhibitors, methods for their discovery, and their use as therapeutic agents for treating certain disorders.
|
|
WO/2009/027679A1 |
A process for the production of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Formula (I) which process comprises:(a) coupling a compound of formula (II) to a compound of formula (III) to form a compound of fo...
|
|
WO/2009/021404A1 |
(1S, 2s, 3S, 4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydro
xyl- cyclopentyl-1- carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods ther...
|
|
WO/2009/022633A1 |
Disclosed is a novel and excellent therapeutic or prophylactic agent for dementia, schizophrenia or the like, which relies on its serotonin 5-HT5A receptor modulation activity. Disclosed is a bicyclic acylguanidine derivative characteriz...
|
|
WO/2008/138090A1 |
The present invention describes compounds produced from an ammo acid molecule and a fatty acid molecule The compounds being in the form of ammo acid-fatty acid compounds of Formula I being bound by an anhydride linkage, or mixtures there...
|
|
WO/2008/124097A2 |
Disclosed herein are crystalline compounds of formula (I), wherein A+ represents y hydroxylated aliphatic ammonium species; and X and Y independently represent leaving groups.
|
|
WO/2008/121322A1 |
The present invention relates, in general, to neuroblastoma and, in particular, to a method of treating neuroblastoma tumors, including refractory neuroblastoma tumors. The invention also relates to compounds and compositions suitable fo...
|
|
WO/2008/115999A1 |
This invention is directed to compounds of formula (I), wherein A, B, m, n, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodr...
|
|
WO/2008/105441A1 |
Disclosed is a water-soluble poly(amino acid) compound represented by the general formula (I) or a salt thereof. The compound is a novel water-soluble compound having an inhibitory effect on the absorption of phosphorus in vivo. (I) wher...
|
|
WO/2008/101309A1 |
The present invention describes compounds produced from a creatine molecule and a fatty acid molecule. The compounds being in the form of creatine-fatty acid compounds being bound by an anhydride linkage, or mixtures thereof made by reac...
|
|
WO/2008/101310A1 |
The present invention describes compounds produced from a creatine molecule and a fatty acid molecule. The compounds being in the form of creatine-fatty compounds bound by an amide linkage, or mixtures thereof produced by reacting creati...
|
|
WO/2008/083056A2 |
Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (ther...
|
|
WO/2008/074403A2 |
Disclosed are compounds of formula (I) or the salts thereof, wherein R1 represents an optionally substituted amino group or analogous group according to claim 1, and R2 to R7 are defined as indicated in claim 1. Said compounds are suitab...
|
|
WO/2008/061456A1 |
The present invention discloses a new biguanidine compound, i.e. folacin-metformin, and its manufacture with inorganic salt of metformin as raw material. Compared with metformin, the compound has the same clinic curative effect, such as ...
|
|
WO/2008/059159A1 |
The invention relates to novel compounds of polyoxyalkylenediguanidine type of formula (I): with A representing formula (II): and salts thereof. It also relates to a cosmetic composition comprising, in a cosmetically acceptable medium, a...
|
|
WO/2008/051733A2 |
A polymeric biguanide composition comprising less than 18 mol% of terminal amine groups as measured by 13C NMR. The polymeric biguanide composition also is characterized by a relative increase in the molar concentration of terminal guani...
|
|
WO/2008/040947A2 |
The present invention relates to compounds useful in the preparation of diazoalkanes in general (such as diazomethane, diazoethane, diazopropane, diazobutane and homologues) and to diazomethane (CH2=N=N) in particular. The compounds chos...
|
|
WO/2008/040979A1 |
The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists.
|
|
WO/2008/039162A1 |
The invention relates to polyguanidine synthesis. The inventive method for producing polyguanidines consists in polycondensing a guanidine salt with diamine during heating in the presence of an organic acid or a mixture of organic acids....
|
|
WO/2008/031212A1 |
The present invention relates to a conjugated salt of creatine and pyroglutamic acid The salt is water soluble and stable and can be used for the regulation of athletic and cognitive functions in a mammal The invention also discloses a p...
|
